Multiple Sclerosis Journal · 2019 · 55 citations · 30 references
MedicineNeurologyNeuroscienceClinical NeurosciencePediatric DisabilityPediatric NeurologyBrain ImagingDevelopmental NeurologyMultiple SclerosisNeurological AssessmentPediatric Neurologic DisordersPediatric NeuropathologyBrain Growth CurvesDisability Status AnalysisDisability Status DeterminationFollow-up DurationHigh-resolution Magnetic Resonance ImagingVolume ChangeWhite Matter InvolvementWhite Matter Lesions
BACKGROUND: Paediatric multiple sclerosis (pedMS) patients at a single site were shown to have reduced brain volumes and failure of age-expected brain growth compared to healthy controls. However, the precise time of onset of brain volume loss remains unclear. OBJECTIVE: To longitudinally study brain volumes in a multi-centre European cohort at first presentation and after 2 years. METHODS: Brain volumes of high-resolution magnetic resonance imaging (MRI) data from 37 pedMS patients at first presentation prior to steroid therapy and at 2-year follow-up ( n = 21) were compared to matched longitudinal MRI data from the NIH Paediatric MRI Data Repository. RESULTS: Patients showed significantly reduced whole brain, grey and white matter and increased ventricular volumes at initial presentation and at follow-up compared to controls. Over 2 years, patients exhibited significant reduction of whole brain and white matter volumes, accompanied by increased ventricular volume. Brain volume loss at follow-up correlated with a higher number of infratentorial lesions, relapses and an increased Expanded Disability Status Scale (EDSS) score. CONCLUSIONS: In pedMS patients, brain volume loss is present already at first clinical presentation and accelerated over 2 years. Increased disease activity is associated with more severe brain volume loss. MRI brain volume change might serve as an outcome parameter in future prospective pedMS studies.
30
Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
Stephen M. Smith, Yongyue Zhang, Mark Jenkinson et al. · NeuroImage · 2002 · 2.1K citations
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni et al. · New England Journal of Medicine · 2016 · 2K citations · Full text
Life Sciences, Immunology, Neurology +17
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text
Life Sciences, Immunology, Neurology +17
Lauren Krupp, Marc Tardieu, Maria Pia Amato et al. · Multiple Sclerosis Journal · 2013 · 1.1K citations
Medicine, Neurology, Pediatrics +15
Natural History of Multiple Sclerosis with Childhood Onset
Christel Renoux, Sandra Vukusic, Yann Mikaeloff et al. · New England Journal of Medicine · 2007 · 591 citations · Full text